What we do Windlas Biotech Ltd manufactures and trades pharmaceutical products focusing on CDMO services, domestic trade generics, OTC brands, and exports, operating WHO-GMP plants in Dehradun. |
Founded in 2,001 |
Market share Leading domestic generic CDMO with growing market share, serving 757 customers and 5,582 products; expanding presence in trade generics and export markets. |
Problem solved Provides affordable, high-quality complex generic medicines with specialized delivery formats addressing chronic and sub-chronic disease treatment needs. |
Top clients or who we serve Serves Indian pharmaceutical companies, government institutional buyers, and international markets in emerging regions; primarily B2B with some institutional sales. |
Key management MD Hitesh Windlass (IIT-BHU, Univ. of Chicago MBA), CEO Komal Gupta (CA, CS, ICWA), Independent Chairman Vivek Dhariwal (IIT Bombay), plus experienced Directors. |
Our journey and innovations Established 2001, converted to public in 2021, expanded capacity over 7 billion units tablets/capsules, launched injectable Plant-V, patented complex generics technology. |
Where we operate Primarily India with exports to about 10 countries across emerging and semi-regulated markets. |
Top products or what we offer CDMO formulations including fixed-dose, modified release, injectables, trade generics brands, and OTC medicines with approx. 400 domestic and 80 export products. |
Top brands Own portfolio of 400+ trade generic brands and 80+ export products; 99% proprietary formulation IP; strong chronic and complex generic product focus. |
Raw materials needed Pharmaceutical active ingredients and excipients sourced globally adhering to robust vendor assessment and approvals. |
Raw materials supplier Multiple vetted suppliers including those approved by customers; globally sourced raw materials for complex generics. |
Recurring vs cyclical contribution Revenue primarily recurring from long-term CDMO contracts and steady trade generic sales; cyclical exposure limited through diversified segments. |
Our industry position Established market leader in India's generic formulations CDMO segment with robust growth in trade generics and rising export footprint. |
Financial highlights FY25 revenue ~Rs 760 Cr with 21% YoY growth, PAT Rs 61 Cr, EBITDA ~12.7%, EPS Rs 29.19, strong liquidity with net debt-free status. |
Geographical revenue split Majority revenue from domestic Indian market and growing exports to emerging/specialty markets internationally. |
Order book - |
Whats driving growth Growth driven by capacity expansions, new complex generics launches, increased institutional sales, export market penetration, and product innovation. |
Our future plans Expanding manufacturing with Plant-6 oral solids, focusing on injectables, new product development, and maintaining leadership in complex generics. |
Our green promise Committed to sustainable manufacturing practices with ongoing CSR activities in healthcare, education, and environmental welfare. |
Our people and values 1346 employees fostering innovation, quality, and ethical business with strong focus on talent development and employee stock ownership. |
Key challenges ahead Risks include regulatory compliance, raw material cost volatility, competition, and execution on capacity expansions. |
Interesting facts Has over 5,500 generic formulations, strong IP ownership on 99% products, and completed India’s highest capsule/tablet capacity expansion recently. |
Risks and strategy Mitigates regulatory, supply chain and market risks via robust quality systems, diversified clients, and continuous R&D investment. |
